Askbio France, Sas, A Subsidiary Of Askbio Inc.

This early-stage trial tests a gene therapy called AB-1001 in 5 adults with early Huntington's disease. The therapy is injected directly into the brain to try to slow the disease. The main goal is to check safety and side effects, while also looking at brain changes on MRI scans.